Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S (2024) Hypopituitarism. Lancet, In press
Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888–3921. https://doi.org/10.1210/jc.2016-2118
Article CAS PubMed Google Scholar
Regal M, Ramo PÂ, Sierra JÂM, GarcõÂa-Mayor RV (2001) Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 55:735–740
Article CAS PubMed Google Scholar
Wydra A, Czajka-Oraniec I, Wydra J, Zgliczyński W (2023) The influence of growth hormone deficiency on bone health and metabolism. Reumatologia 61:239–247. https://doi.org/10.5114/reum/170244
Article PubMed PubMed Central Google Scholar
Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39:440–488. https://doi.org/10.1210/er.2018-00005
Mazziotti G, Porcelli T, Bianchi A et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15–20. https://doi.org/10.1530/EJE-10-0125
Article CAS PubMed Google Scholar
Mazziotti G, Mormando M, Cristiano A et al (2014) Association between L-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol 170:893–899. https://doi.org/10.1530/EJE-14-0097
Article CAS PubMed Google Scholar
Chiloiro S, Frara S, Gagliardi I et al (2023) Cholecalciferol use is associated with a decreased risk of incident morphometric vertebral fractures in acromegaly. J Clin Endocrinol Metab 109:e58–e68. https://doi.org/10.1210/clinem/dgad493
Article PubMed PubMed Central Google Scholar
Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporos Int. https://doi.org/10.1007/s00198-002-1345-4
Eastell R, Szulc P (2017) Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 5:908–923. https://doi.org/10.1016/S2213-8587(17)30184-5
Uygur MM, Frara S, di Filippo L, Giustina A (2023) New tools for bone health assessment in secreting pituitary adenomas. Trends Endocrinol Metab 34:231–242. https://doi.org/10.1016/j.tem.2023.01.006
Article CAS PubMed Google Scholar
Samelson EJ, Broe KE, Xu H et al (2019) Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the bone microarchitecture international consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol 7:34–43. https://doi.org/10.1016/S2213-8587(18)30308-5
Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535–559
Article CAS PubMed PubMed Central Google Scholar
Rosén T, Wilhelmsen L, Landin-Wilhelmsen K et al (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240–245
Mazziotti G, Lania AG, Canalis E (2022) Skeletal disorders associated with the growth hormone–insulin-like growth factor 1 axis. Nat Rev Endocrinol 18:353–365. https://doi.org/10.1038/s41574-022-00649-8
Article CAS PubMed Google Scholar
Canalis E (2009) Growth factor control of bone mass. J Cell Biochem 108:769–777. https://doi.org/10.1002/jcb.22322
Article CAS PubMed PubMed Central Google Scholar
Ohlsson C, Bengtsson B-Å, Isaksson OGP et al (1998) Growth hormone and bone*. Endocr Rev 19:55–79
Yuen KCJ, Koltowska-Haggstrom M, Cook DM et al (2013) Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction. Eur J Endocrinol 169:511–519. https://doi.org/10.1530/EJE-13-0280
Article CAS PubMed Google Scholar
Baroncelli GI, Bertelloni S, Sodini F, Saggese G (2004) Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf) 60:175–184. https://doi.org/10.1046/j.1365-2265.2003.01949.x
Tritos NA, Hamrahian AH, King D et al (2012) A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: A KIMS database analysis. Eur J Endocrinol 167:343–351. https://doi.org/10.1530/EJE-12-0070
Article CAS PubMed PubMed Central Google Scholar
Baer TG, Agarwal S, Chen S et al (2020) Deficits in bone geometry in growth hormone-deficient prepubertal boys revealed by high-resolution peripheral quantitative computed tomography. Horm Res Paediatr 92:293–301. https://doi.org/10.1159/000506229
Yang H, Yan K, Xu Y et al (2019) Bone microarchitecture and volumetric bone density impairment in young male adults with childhood-onset growth hormone deficiency. Eur J Endocrinol 180:145–153. https://doi.org/10.1530/EJE-18-0711
Mazziotti G, Doga M, Frara S et al (2016) Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52:103–110. https://doi.org/10.1007/s12020-015-0738-z
Article CAS PubMed Google Scholar
Bex M, Abs R, Maiter D et al (2002) The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: A 2-year open randomized controlled multicenter trial. J Bone Miner Res 17:1081–1094. https://doi.org/10.1359/jbmr.2002.17.6.1081
Article CAS PubMed Google Scholar
Barake M, Klibanski A, Tritos NA (2014) Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99:852–860. https://doi.org/10.1210/jc.2013-3921
Article CAS PubMed Google Scholar
Appelman-Dijkstra NM, Claessen KMJA, Hamdy NAT et al (2014) Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the leiden cohort study. Clin Endocrinol (Oxf) 81:727–735. https://doi.org/10.1111/cen.12493
Article CAS PubMed Google Scholar
Conway GS, Szarras-Czapnik M, Racz K et al (2009) Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 160:899–907. https://doi.org/10.1530/EJE-08-0436
Article CAS PubMed Google Scholar
Boot AM, Van Der Sluis IM, Krenning EP, De Muinck K-S (2009) Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res 71:364–371. https://doi.org/10.1159/000223422
Article CAS PubMed Google Scholar
Mazziotti G, Bianchi A, Bonadonna S et al (2006) Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: Influence of GH replacement therapy. J Bone Miner Res 21:520–528. https://doi.org/10.1359/jbmr.060112
Article CAS PubMed Google Scholar
Elbornsson M, Götherström G, Bosæus I et al (2012) Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166:787–795. https://doi.org/10.1530/EJE-11-1072
Article CAS PubMed PubMed Central Google Scholar
Rossini A, Lanzi R, Galeone C et al (2021) Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy. Endocrine 74:666–675. https://doi.org/10.1007/s12020-021-02835-6
Article CAS PubMed Google Scholar
Mo D, Fleseriu M, Qi R et al (2015) Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3:331–338. https://doi.org/10.1016/S2213-8587(15)00098-4
Article CAS PubMed Google Scholar
Shoback D, Rosen CJ, Black DM et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgaa048
Biermasz NR, Hamdy NAT, Pereira AM et al (2004) Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol (Oxf) 60:568–575. https://doi.org/10.1111/j.1365-2265.2004.02021.x
Article CAS PubMed Google Scholar
Biermasz NR, Hamdy NAT, Janssen YJH, Roelfsema F (2001) Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab 86:3079–3085
留言 (0)